Perspective

*Author for correspondence:

E-mail Address: guterres_rj@yahoo.com.br

Laboratório de Tecnologia Imunológica, Instituto de Tecnologia em Imunobiológicos, Vice-Diretoria de Desenvolvimento Tecnológico, Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, 21040-360, Brazil

Search for more papers by this author

Mayla Abrahim

https://orcid.org/0000-0001-5613-1059

Search for more papers by this author

Patrícia Cristina da Costa Neves

https://orcid.org/0000-0002-5589-9354

Search for more papers by this author

Published Online:11 Jul 2023https://doi.org/10.2217/imt-2023-0027

View article

Abstract

Studies on the development of mRNA vaccines for central nervous system tumors have used gene expression profiles, clinical data and RNA sequencing from sources such as The Cancer Genome Atlas and Chinese Glioma Genome Atlas to identify effective antigens. These studies revealed several immune subtypes of glioma, each one linked to unique prognoses and genetic/immune-modulatory changes. Potential antigens include ARPC1B, BRCA2, COL6A1, ITGB3, IDH1, LILRB2, TP53 and KDR, among others. Patients with immune-active and immune-suppressive phenotypes were found to respond better to mRNA vaccines. While these findings indicate the potential of mRNA vaccines in cancer therapy, further research is required to optimize administration and adjuvant selection, and precisely identify target antigens.

Plain language summary

Scientists study special vaccines for hard-to-treat brain tumors. They looked at things, such as information about patients and the small parts of cells that make up the tumor, to find ways to help. They found that brain tumors can make our body's defenses act differently. They also found some possible targets and unique defense patterns that are special to each patient when fighting these tumors. Patients with these special defenses and good targets might respond better to treatment with vaccines. This is exciting because it means that in the future, we might have treatments made for each person. But we still need to do more research to figure out how to get these vaccines to the tumor, so this research gives us hope that we can find better treatments and more choices for people with brain cancer. If we keep researching, we might find even better treatments in the future.

Tweetable abstract

Personalized mRNA vaccines show potential for treating gliomas, with gene profiling and clinical data revealing immune subtypes linked to treatment response. Further research is needed to optimize delivery and target selection. #mRNAVaccines #CNSCancer

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Louis DN, Perry A, Wesseling P et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23(8), 1231–1251 (2021).
Medline CASGoogle Scholar
2. Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 32(4), e13062 (2022).
MedlineGoogle Scholar
3. Bothwell SW, Janigro D, Patabendige A. Cerebrospinal fluid dynamics and intracranial pressure elevation in neurological diseases. Fluids Barriers CNS 16(1), 9 (2019).
MedlineGoogle Scholar
4. Simon MJ, Iliff JJ. Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. Biochim. Biophys. Acta 1862(3), 442–451 (2016).
Medline CASGoogle Scholar
5. Faraj CA, Snyder RI, McCutcheon IE. Intracranial emergencies in neurosurgical oncology: pathophysiology and clinical management. Emerg. Cancer Care 1(1), 13 (2022).
Google Scholar
6. Lamba N, Fick T, Nandoe Tewarie R, Broekman ML. Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making. J. Neurooncol. 140(1), 5–13 (2018).
MedlineGoogle Scholar
7. Nabors LB, Ammirati M, Bierman PJ et al. Central nervous system cancers. J. Natl Comprehens. Cancer Netw. 11(9), 1114–1151 (2013).
CASGoogle Scholar
8. Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int. J. Med. Sci. 9(3), 193–199 (2012).
MedlineGoogle Scholar
9. Dutta V. Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. J. Cancer Res. Ther. 7(3), 264 (2011).
MedlineGoogle Scholar
10. Wilkes GM. Targeted therapy: attacking cancer with molecular and immunological targeted agents. Asia Pac. J. Oncol. Nurs. 5(2), 137–155 (2018).
MedlineGoogle Scholar
11. Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ. Tumour treating fields therapy for glioblastoma: current advances and future directions. Br. J. Cancer 124(4), 697–709 (2021).
MedlineGoogle Scholar
12. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLOS ONE 10(5), e0125269 (2015).
MedlineGoogle Scholar
13. Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis. 8(4), e2753–e2753 (2017).
Medline CASGoogle Scholar
14. Wenger C, Giladi M, Bomzon Z, Salvador R, Basser PJ, Miranda PC. Modeling tumor treating fields (TTFields) application in single cells during metaphase and telophase. Presented at: 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, Milan, Italy, 25–29 August 2015.
Google Scholar
15. Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, Tran PT. Tumor treating fields: at the crossroads between physics and biology for cancer treatment. Front. Oncol. 10, doi: 10.3389/fonc.2020.575992 (2020).
Google Scholar
16. Stupp R, Taillibert S, Kanner AA et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA 314(23), 2535 (2015).
Medline CASGoogle Scholar
17. Stupp R, Taillibert S, Kanner A et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA 318(23), 2306 (2017).
Medline CASGoogle Scholar
18. Stupp R, Wong ET, Kanner AA et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48(14), 2192–2202 (2012).
MedlineGoogle Scholar
19. Lassman AB, Joanta-Gomez AE, Pan PC, Wick W. Current usage of tumor treating fields for glioblastoma. Neurooncol. Adv. 2(1), 1–9 (2020).
MedlineGoogle Scholar
20. Yang T, Kong Z, Ma W. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Hum. Vaccin. Immunother. 17(2), 546–553 (2021).
Medline CASGoogle Scholar
21. Yang K, Wu Z, Zhang H et al. Glioma targeted therapy: insight into future of molecular approaches. Mol. Cancer 21(1), 39 (2022). • Discusses insights into advancing neuro-oncology treatments.
Medline CASGoogle Scholar
22. Khasraw M, Fujita Y, Lee-Chang C, Balyasnikova IV, Najem H, Heimberger AB. New approaches to glioblastoma. Annu Rev Med 73(1), 279–292 (2022).
MedlineGoogle Scholar
23. Suarez-Meade P, Marenco-Hillembrand L, Sherman WJ. Neuro-oncologic emergencies. Curr Oncol Rep 24(8), 975–984 (2022).
MedlineGoogle Scholar
24. Picca A, Guyon D, Santonocito OS et al. Innovating strategies and tailored approaches in neuro-oncology. Cancers (Basel) 14(5), 1124 (2022). • Discusses insights into advancing neuro-oncology treatments.
Medline CASGoogle Scholar
25. Liau LM, Ashkan K, Brem S et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma. JAMA Oncol. 9(1), 112 (2023). •• Debate arises over autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma treatment: breakthrough or illusion in neuro-oncology?
MedlineGoogle Scholar
26. Preusser M, van den Bent MJ. Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana? Neuro Oncol. 25(4), 631–634 (2023). •• Debate arises over autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma treatment: breakthrough or illusion in neuro-oncology?
MedlineGoogle Scholar
27. Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B. Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin. Biol. Ther. 21(2), 201–218 (2021).
Medline CASGoogle Scholar
28. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14–20 (2020).
Medline CASGoogle Scholar
29. Lundstrom K. Latest development on RNA-based drugs and vaccines. Future Sci. OA 4(5), 1–10 (2018).
CASGoogle Scholar
30. Guevara ML, Persano F, Persano S. Advances in Lipid nanoparticles for mRNA-based cancer immunotherapy. Front. Chem. 8, doi: 10.3389/fchem.2020.589959 (2020).
MedlineGoogle Scholar
31. Chen Z, Wang X, Yan Z, Zhang M. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development. Cancer Med. 11(13), 2711–2726 (2022).
Medline CASGoogle Scholar
32. Ma S, Ba Y, Ji H, Wang F, Du J, Hu S. Recognition of Tumor-associated antigens and immune subtypes in glioma for mRNA vaccine development. Front. Immunol. 12, doi: 10.3389/fimmu.2021.738435 (2021).
Google Scholar
33. Zhong H, Liu S, Cao F et al. Dissecting tumor antigens and immune subtypes of glioma to develop mRNA vaccine. Front. Immunol. 12, doi: 10.3389/fimmu.2021.709986 (2021).
Google Scholar
34. Ye L, Wang L, Yang J et al. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development. J. Transl. Med. 19(1), 352 (2021).
Medline CASGoogle Scholar
35. Zhou Q, Yan X, Zhu H et al. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma. Theranostics 11(20), 9775–9790 (2021).
Medline CASGoogle Scholar
36. Ye L, Wang L, Yang J et al. Identification of tumor antigens and immune landscape in glioblastoma for mRNA vaccine development. Front. Genet. 12, doi: 10.3389/fgene.2021.701065 (2021).
Google Scholar
37. Rose M, Cardon T, Aboulouard S et al. Surfaceome Proteomic of glioblastoma revealed potential targets for immunotherapy. Front. Immunol. 12, doi: 10.3389/fimmu.2021.746168 (2021).
Google Scholar
38. Lin H, Wang K, Xiong Y et al. Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development. Front. Immunol. 13, doi:10.3389/fimmu.2022.773264 (2022).
Google Scholar
39. Wu C, Qin C, Long W, Wang X, Xiao K, Liu Q. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. J Big Data 9(1), 92 (2022).
MedlineGoogle Scholar
40. Daneman R, Prat A. The blood–brain barrier. Cold Spring Harbor Perspect. Biol. 7(1), a020412 (2015).
MedlineGoogle Scholar
41. Hersh AM, Alomari S, Tyler BM. Crossing the blood–brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int. J. Mol. Sci. 23(8), 4153 (2022). •• Discusses drug delivery in neuro-oncology.
Medline CASGoogle Scholar
42. Nitika, Wei J, Hui A-M. The delivery of mRNA vaccines for therapeutics. Life 12(8), 1254 (2022). • Discusses drug delivery in neuro-oncology.
Medline CASGoogle Scholar
43. Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed. Res. Int. 2014, 1–37 (2014).
Google Scholar
44. Kadry H, Noorani B, Cucullo L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17(1), 69 (2020).
MedlineGoogle Scholar
45. Wu Z, Li T. Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives. Pharm. Res. 38(3), 473–478 (2021).
Medline CASGoogle Scholar
46. Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40(11), 1586–1600 (2022).
Medline CASGoogle Scholar
47. Ratnam NM, Gilbert MR, Giles AJ. Immunotherapy in CNS cancers: the role of immune cell trafficking. Neuro. Oncol. 21(1), 37–46 (2019).
Medline CASGoogle Scholar
48. Rzymski P, Szuster-Ciesielska A, Dzieciątkowski T, Gwenzi W, Fal A. mRNA vaccines: the future of prevention of viral infections? J. Med. Virol. 95(2), e28572 (2023).
Medline CASGoogle Scholar
49. Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20(1), 41 (2021).
Medline CASGoogle Scholar
50. Jung SM, Kim W-U. Targeted immunotherapy for autoimmune disease. Immune Netw. 22(1), e9 (2022).
MedlineGoogle Scholar
51. Van Hoecke L, Verbeke R, Dewitte H et al. mRNA in cancer immunotherapy: beyond a source of antigen. Mol. Cancer 20(1), 48 (2021).
Medline CASGoogle Scholar
52. Fitzgerald KD, Semler BL. Bridging IRES elements in mRNAs to the eukaryotic translation apparatus. Biochim. Biophys. Acta 1789(9–10), 518–528 (2009).
Medline CASGoogle Scholar
53. Murat P, Tellam J. Effects of messenger RNA structure and other translational control mechanisms on major histocompatibility complex-I mediated antigen presentation. Wiley Interdiscip. Rev. RNA 6(2), 157–171 (2015).
Medline CASGoogle Scholar
54. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20(11), 651–668 (2020).
Medline CASGoogle Scholar
55. Kim SC, Sekhon SS, Shin W-R et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol. Cell. Toxicol. 18(1), 1–8 (2022).
Medline CASGoogle Scholar
56. Jia Y, Wei Y. Modulators of MicroRNA function in the immune system. Int. J. Mol. Sci. 21(7), 2357 (2020).
Medline CASGoogle Scholar
57. Beck JD, Reidenbach D, Salomon N et al. mRNA therapeutics in cancer immunotherapy. Mol. Cancer 20(1), 69 (2021).
Medline CASGoogle Scholar
58. Scheetz L, Park KS, Li Q et al. Engineering patient-specific cancer immunotherapies. Nat. Biomed. Eng. 3(10), 768–782 (2019).
Medline CASGoogle Scholar
59. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs. Nat. Rev. Drug Discov. 13(10), 759–780 (2014).
Medline CASGoogle Scholar
60. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat. Rev. Drug Discov. 17(4), 261–279 (2018).
Medline CASGoogle Scholar
61. Bringmann A, Held SAE, Heine A, Brossart P. RNA vaccines in cancer treatment. J. Biomed. Biotechnol. 2010, 1–12 (2010).
Google Scholar
62. Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer vaccines, adjuvants, and delivery systems. Front. Immunol. 12, doi: 10.3389/fimmu.2021.627932 (2021).
MedlineGoogle Scholar
63. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat. Rev. Cancer 12(4), 307–313 (2012).
Medline CASGoogle Scholar
64. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118(6), 1991–2001 (2008).
Medline CASGoogle Scholar
65. Supabphol S, Li L, Goedegebuure SP, Gillanders WE. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert Opin. Investig. Drugs 30(5), 529–541 (2021).
Medline CASGoogle Scholar
66. Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8(1), 9 (2023).
Medline CASGoogle Scholar
67. Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int. Immunol. 28(8), 411–419 (2016).
Medline CASGoogle Scholar
68. Fang X, Guo Z, Liang J et al. Neoantigens and their potential applications in tumor immunotherapy (review). Oncol. Lett. 23(3), 88 (2022).
Medline CASGoogle Scholar
69. Baghban R, Roshangar L, Jahanban-Esfahlan R et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 18(1), 59 (2020).
MedlineGoogle Scholar
70. Anderson NM, Simon MC. The tumor microenvironment. Curr. Biol. 30(16), R921–R925 (2020).
Medline CASGoogle Scholar
71. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19(11), 1423–1437 (2013).
Medline CASGoogle Scholar
72. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45), 5904–5912 (2008).
Medline CASGoogle Scholar
73. Shemesh CS, Hsu JC, Hosseini I et al. Personalized Cancer vaccines: clinical landscape, challenges, and opportunities. Mol. Ther. 29(2), 555–570 (2021).
Medline CASGoogle Scholar
74. Wang D-R, Wu X-L, Sun Y-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct. Target Ther. 7(1), 331 (2022).
Medline CASGoogle Scholar
75. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol. Immunol. 17(8), 807–821 (2020).
Medline CASGoogle Scholar
76. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39, 1–6 (2016).
Medline CASGoogle Scholar
77. Rostamizadeh L, Molavi O, Rashid M et al. Recent advances in cancer immunotherapy: modulation of tumor microenvironment by Toll-like receptor ligands. Bioimpacts 12(3), 261–290 (2022).
Medline CASGoogle Scholar
78. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat. Rev. Cancer 21(6), 345–359 (2021).
Medline CASGoogle Scholar
79. Disis ML. Immune regulation of cancer. J. Clin. Oncol. 28(29), 4531–4538 (2010).
Medline CASGoogle Scholar
80. Thol K, Pawlik P, McGranahan N. Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. Genome Med. 14(1), 137 (2022).
MedlineGoogle Scholar
81. Shelton SE, Nguyen HT, Barbie DA, Kamm RD. Engineering approaches for studying immune-tumor cell interactions and immunotherapy. iScience 24(1), doi: 10.1016/j.isci.2020.101985 (2021).
MedlineGoogle Scholar
82. Baghban R, Roshangar L, Jahanban-Esfahlan R et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 18(1), 59 (2020).
MedlineGoogle Scholar
83. Liu D, Chen J, Hu X et al. Imaging-genomics in glioblastoma: combining molecular and imaging signatures. Front. Oncol. 11, doi: 10.3389/fonc.2021.699265 (2021).
Google Scholar
84. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 12(1), 8 (2020).
MedlineGoogle Scholar
85. Huff AL, Jaffee EM, Zaidi N. Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. J. Clin. Invest. 132(6), e156211 (2022).
Medline CASGoogle Scholar
86. Binnewies M, Roberts EW, Kersten K et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24(5), 541–550 (2018).
Medline CASGoogle Scholar
87. Huff AL, Jaffee EM, Zaidi N. Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. J. Clin. Invest. 132(6), e156211 (2022).
Medline CASGoogle Scholar
88. Li Y, Su Z, Zhao W et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat. Cancer 1(9), 882–893 (2020).
Medline CASGoogle Scholar
89. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat. Rev. Drug Discov. 17(4), 261–279 (2018).
Medline CASGoogle Scholar
90. Kim W, Liau LM. IDH mutations in human glioma. Neurosurg. Clin. N. Am. 23(3), 471–480 (2012).
MedlineGoogle Scholar
91. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol. 15(7), 405–417 (2019).
MedlineGoogle Scholar
92. Han S, Liu Y, Cai SJ et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br. J. Cancer 122(11), 1580–1589 (2020).
MedlineGoogle Scholar
93. Mirchia K, Richardson TE. Beyond IDH-mutation: emerging molecular diagnostic and prognostic features in adult diffuse gliomas. Cancers (Basel) 12(7), 1817 (2020).
Medline CASGoogle Scholar
94. Kaminska B, Czapski B, Guzik R, Król S, Gielniewski B. Consequences of IDH1/2 mutations in gliomas and an assessment of inhibitors targeting mutated IDH proteins. Molecules 24(5), 968 (2019).
MedlineGoogle Scholar
95. Guo C, Pirozzi CJ, Lopez GY, Yan H. Isocitrate dehydrogenase mutations in gliomas. Curr. Opin. Neurol. 24(6), 648–652 (2011).
MedlineGoogle Scholar
96. Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics 14(2), 284–297 (2017).
MedlineGoogle Scholar
97. Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma. JAMA Neurol. 71(10), 1319 (2014).
MedlineGoogle Scholar

Vol. 15, No. 13

Metrics

Downloaded 156 times

History

Received 3 February 2023

Accepted 20 June 2023

Published online 11 July 2023

Published in print September 2023

Information

Keywords

Author contributions

A Guterres was responsible for study conception and design. A Guterres, M Abrahim and PCC Neves were responsible for data collection and analysis. A Guterres, M Abrahim and PCC Neves were responsible for interpretation of data. All authors reviewed and contributed to revisions of the manuscript.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

The role of immune subtyping in glioma mRNA vaccine development

Abstract

Plain language summary

Tweetable abstract

References